Alto Neuroscience
ANRO
Market cap $304M

11.29 USD

+0.04

0.36%

At close Oct 9, 4:00 PM EDT

After hours

11.29

+0.00

0.00%

1 day

0.36%

5 days

13.58%

1 month

-19.99%

3 months

-14.14%

6 months

-23.35%

Year to date

-45.46%

1 year

-45.46%

5 years

-45.46%

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 78

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

12% more funds holding

Funds holding: 51 [Q1] → 57 (+6) [Q2]

9.75% more ownership

Funds ownership: 59.15% [Q1] → 68.9% (+9.75%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

19% less capital invested

Capital invested by funds: $244M [Q1] → $198M (-$46.1M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$29

157%

upside

Avg. target

$29

157%

upside

High target

$29

157%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Wedbush Laura Chico 51% 1-year accuracy 36 / 70 met price target	157%upside $29	Outperform Reiterated	10 Sept 2024
Wedbush Laura Chico 51% 1-year accuracy 36 / 70 met price target	157%upside $29	Outperform Initiated	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a peer-review publication demonstrating baseline cognitive performance is not a moderator of response to standard-of-care antidepressants in patients with major depressive disorder (MDD). The analysis, titled “Baseline Cognition Is Not Associated With Depression Out.

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

Alto Neuroscience to Participate in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in September: Alto Investor Day Focused on ALTO-100 in Major Depressive Disorder, September 9th 2024: Ahead of topline data expected in October 2024 f.

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. “Over the recent months we achieved several important milestones for our company and for the field of precision psychiatry as a whole,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Completing the enrollment of 301 patients in our Phase 2b study of A.

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

24/7 Wall Street

5 Stocks Under $10 Growing 50% Or More

Are you looking for low-cost stocks to add to your portfolio?

5 Stocks Under $10 Growing 50% Or More

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Company has been awarded $11.7 million by the Wellcome Trust to advance the clinical development of lead candidate ALTO-100 through a Phase 2b study in patients with bipolar depression characterized by a cognitive biomarker. The Company has initiated this.

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of enrollment in its Phase 2b study of ALTO-100 in adults with major depressive disorder (MDD). Topline results from this study are expected to be reported in October 2024. “The completion of enrollment in this study marks an important achievement,”.

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101, a novel PDE4 inhibitor in development for the treatment of cognitive impairment associated with schizophrenia (CIAS). Alto expects to report top-line data from the Phase 2 study in the second half of 2025. “We are excited to initiate our sixth Phase 2 study as a company, across our pipelin.

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive business award for audacious leaders who disrupt markets, revolutionize sectors, and have a transformational impact on lives. Over the past four decades, the program has recognized daring entrepreneurs.

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On

One of the best ways to be successful in the stock market is by identifying under-the-radar stocks before they blow up. All of today's biggest and most valuable companies were once entirely unknown.

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m. ET, and management will host one-on-one meetings with investors. A live webcast of the fireside chat will be available on the Events.

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™